LGVN - Longeveron LLC

LGVN - Longeveron LLC

https://longeveron.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire • 3 weeks, 5 days ago • score: 0.04

Longeveron will present and host investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025.

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Longeveron ( NASDAQ:LGVN )

Benzinga • 3 weeks, 5 days ago • score: 0.03

MIAMI, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Longeveron Inc. LGVN, a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the H.C.

Longeveron Posts 32% Revenue Drop in Q2

Motley Fool • 1 month ago • score: 0.20

Longeveron ( NASDAQ:LGVN ) , a clinical-stage biotechnology firm focused on stem cell therapies for rare and aging-related diseases, released its second quarter earnings on August 13, 2025.The most notable headline was a deepening net loss for the six months ended June 30, 2025, driven by ...

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

GlobeNewswire • 1 month, 1 week ago • score: 0.01

Longeveron will report Q2 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close.

Longeveron® Appoints Than Powell as Chief Business Officer

Business Insider • 2 months, 2 weeks ago • score: 0.32

Mr. Powell to oversee Longeveron's partnering and international strategy efforts

Longeveron® Appoints Than Powell as Chief Business Officer - Longeveron ( NASDAQ:LGVN )

Benzinga • 2 months, 2 weeks ago • score: 0.31

Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 ( GLOBE NEWSWIRE ) -- Longeveron Inc.

Longeveron® Appoints Than Powell as Chief Business Officer

GlobeNewswire • 2 months, 2 weeks ago • score: 0.24

Than Powell appointed as Longeveron CBO to lead overall business strategy, Alzheimer's program partnering and HLHS program international strategy.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Longeveron Inc., a clinical-stage biotechnology company, is dedicated to developing cell therapies for life-threatening and aging-related conditions. The company is headquartered in Miami, Florida.

52W High

$2.48

52W Low

$0.63

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.18

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

3.17

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-49.61

EV/Revenue (<3 favorable)

3.51

P/S (TTM) (<3 favorable)

7.94

P/B (<3 favorable)

1.30

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

14.83%

Institutions (25–75% balanced)

6.96%

Shares Outstanding

19,312,200

Float

11,417,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

2,073,000

Gross Profit (TTM)

1,632,000

EPS (TTM)

0.25

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-17.08%

ROE (TTM) (>15% strong)

-1.35%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.33

Momentum

Bearish momentum

Value

-0.0973

Previous

-0.1023

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025